Safety and Efficacy of Rituximab in Systemic Sclerosis (DESIRES): A Double-Blind, Investigator-Initiated, Randomised, Placebo-Controlled Trial

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Safety and Efficacy of Rituximab in Systemic Sclerosis (DESIRES): A Double-Blind, Investigator-Initiated, Randomised, Placebo-Controlled Trial

By National Jewish Health FEATURING Mehrnaz Maleki Fischbach

379 views

August 18, 2022

Join Dr. Mehrnaz Maleki Fischbach Rheumatologist at National Jewish Health as she discusses the article ...
read more ↘ titled: “Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial, The Lancet Rheumatology, Volume 3, Issue 7, 2021, Pages e489-e497, ISSN 2665-9913, https://doi.org/10.1016/S2665-9913(21)00107-7.”
↖ read less

Comments 0